Authors
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETsThe hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.
Latest:
Objective Data Highlight Substantial Benefits With Mirdametinib in NF1-PNFindings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Latest:
The Evolving Treatment Landscape and Patient PerspectivesDrs Jain and Shah discuss the future of patient care in metastatic bladder cancer, while Mr. and Mrs. Ehas share advice for patients with bladder cancer, advice for caregivers and closing thoughts on their overall journey.
Latest:
Optimizing Haploidentical Hematopoietic Stem Cell Transplantation: Enhancing Outcomes in Hematologic Malignancies in Resource-Limited SettingsResearchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.
Latest:
Treatment Experience for a Patient With GVHDA patient with GVHD chronicles his treatment experience, and GVHD experts share thoughts on how to approach treatment.
Latest:
Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal MalignanciesCirculating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.
Latest:
Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate CancerBrian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
Oncology Peer Review On-The-Go: Ofer Sharon, MD, Discusses OncoHost and PROPHETIC Trial for NSCLCOfer Sharon, MD, spoke about the PROphet diagnostic platform for non–small cell lung cancer and the latest interim results from the prospective PROPHETIC trial in the most recent episode of CancerNetwork’s® "Oncology Peer Review On-The-Go" podcast.
Latest:
Bolstering Access to Breast Cancer Screening for Genome MarkersPerformance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Latest:
A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord CompressionMehmet S. Copur, MD, and colleagues examine the case of a 65-year-old who presented with back pain and a large T8 spinal mass, leading to a diagnosis of multiple myeloma with spinal cord compromise.
Latest:
Biomarkers for Response to Anti–PD-1/Anti–PD-L1 Immune Checkpoint Inhibitors: A Large Meta-AnalysisArshiya Mariam, BS, and colleagues report the findings of a large meta-analysis assessing the ability of various biomarkers to predict responses to immune checkpoint inhibition.
Latest:
Oncology Clinical Trials During the COVID-19 PandemicABSTRACT The coronavirus disease 2019 (COVID-19) pandemic has rapidly spread all over the world in the past several months. No effective treatment for COVID-19 has been established. High transmissibility and considerable mortality rates have forced many national governments to implement quarantine measures. Many patients with cancer rely on clinical trials to receive their oncologic care, but the routine conduct of clinical trials has substantially changed because of the COVID-19 pandemic. The oncology research community should implement formal policies based on the guidance given from regulatory agencies, with the goal of minimizing the risks of COVID-19 infection while maintaining appropriate oncologic treatments for patients during this pandemic.
